Rare Disease Biotech Has a Hunger Problem, And Big Pharma Isn't Sharing

The numbers bear this out. Biotech venture funding has slowed since its 2021 peak. When VCs do write checks, they're skewing toward larger, consolidated deals. Series A mega-rounds of $100 million or more are flowing to areas like cell and gene therapy platforms with broad applications. Ultra-rare disease programs with tiny patient populations and decade-plus timelines to approval? They're getting ghosted.

This creates what industry watchers call a two-tier valuation market. Late-stage rare disease assets command eye-popping premiums. Early-stage ones can barely get a meeting.

Over 95% of rare diseases still have no approved treatment. The science to change that might exist, but it's starving for capital while everyone fights over the few programs that already made it through the gauntlet.

Why Pharma Plays It Safe

You can't entirely blame the big companies. Early-stage rare disease research is genuinely brutal.

Patient populations are small, sometimes just a few thousand people worldwide. Clinical trials are hard to recruit for. Manufacturing is complex and expensive, especially for cutting-edge modalities like gene therapy. The whole journey from lab to pharmacy shelf can take 12 to 15 years.

And when you're a publicly traded company answering to Wall Street every quarter, betting billions on something that might not pay off until 2040 is a tough sell. It's much easier, and much more predictable, to buy a drug that's already proven it works and has a clear regulatory path to approval.

Novartis made this calculus explicit when it acquired Avidity Biosciences for $12 billion. It kept the late-stage RNA therapies for rare neuromuscular diseases and literally spun out the earlier-stage programs. The company essentially said: we'll take the steak, you can keep the bread rolls.

The AI Lifeline

So who fills the gap? Increasingly, the answer involves artificial intelligence.

AI-powered drug repurposing (finding new uses for drugs that are already approved and proven safe) is emerging as a cheaper, faster alternative to traditional early discovery. Instead of spending a decade building a molecule from scratch, these platforms scan enormous datasets to find existing drugs that might work for rare diseases nobody thought to test them against.

Companies like Recursion, Healx, and Insilico Medicine are leading this charge. Harvard researchers built a tool called TxGNN specifically designed to match existing drugs to rare diseases that currently have zero treatments. The AI drug repurposing market is projected to grow from $1.23 billion in 2025 to nearly $5.7 billion by 2033.

It's not a perfect solution. AI can identify candidates, but someone still has to run the clinical trials. And even repurposed drugs need funding to get tested in new patient populations. But it dramatically lowers the cost of the riskiest part of drug development: figuring out what might actually work.

Think of it as skipping the appetizer course entirely and going straight to the entrée.

A Policy Patch, Not a Cure

Washington has noticed the problem, kind of. The 2026 Consolidated Appropriations Act, signed in February, extended the rare pediatric disease priority review voucher program through 2029. These vouchers, historically worth $100 to $200 million each, give companies a fast-pass for FDA review that they can use or sell. Jazz Pharmaceuticals sold one for $200 million.

The same law also clarified orphan drug exclusivity rules, resolving years of legal uncertainty that had made investors nervous. And existing incentives (seven years of market exclusivity, tax credits, the FDA's Rare Disease Hub) remain in place.

But incentives at the finish line don't help much if companies can't afford to reach the starting blocks. The fundamental problem remains: the economics of early-stage rare disease research don't work without someone willing to take the first, most expensive bet.

The Bottom Line

Rare disease is booming, for the companies that already did the hard part. Late-stage acquisitions are setting records. Approved orphan drugs are printing money. The steak side of the buffet has never been more crowded.

But the pipeline feeding that buffet is thinning out. Early-stage rare disease biotechs are caught in a brutal squeeze: too risky for big pharma, too small-market for most VCs, and too expensive for anyone without deep pockets and a long time horizon.

AI repurposing and policy tweaks are helping around the margins. But until someone figures out how to make early rare disease bets financially rational again, the 300 million people worldwide living with rare diseases will keep waiting for cures that the market has decided aren't worth the risk.

And that's not a funding strategy. It's a failure of imagination.

Moderna Just Sold a Rare Disease Drug for Pennies on the Dollar

Moderna handed Recordati the commercial rights to a potentially first-in-class rare disease therapy for just $50 million upfront. Leerink analysts called it a "garage sale," and the math backs them up.